ESC Congress 2004: Efficacy and safety of ximelagatran confirmed for stroke prevention in atrial fibrillationAugust 29, 2004European Society of Cardiology Congress (ESC), Munich, Germany: Results presented today from the final pooled analysis of SPORTIF III and V1,2 confirm that ximelagatran - the first oral direct thrombin inhibitor (oral DTI) - is as effective as well-controlled warfarin, the current standard anticoagulant treatment for the prevention of stroke in patients with atrial fibrillation (AF), but without the need for coagulation monitoring or individual dose titration. Patients with AF, an erratic heartbeat which increases the chance of developing a thrombus, are five times more likely to suffer a stroke than those with normal heart rhythm. Studies show that the risk of stroke can be reduced by 62% in AF patients by taking anticoagulant therapy3, but that only half of eligible patients currently receive appropriate anticoagulant treatment4. Although existing anticoagulant treatments are effective, they have limitations. Vitamin K antagonists (VKAs), for example warfarin, are associated with extensive drug and food interactions and require coagulation monitoring and dose titration. "The findings from this detailed analysis of the SPORTIF study programme results are very encouraging as they further demonstrate in two independent studies that ximelagatran is both safe and effective in the prevention of stroke for people with atrial fibrillation. This treatment offers a welcome and long awaited advance in anticoagulation therapy and should see a significantly larger proportion of patients who require treatment actually receiving it - reducing the incidence of stroke," commented Professor Bertil Olsson, co-chairman of the executive steering committee of SPORTIF III & V, Department of Cardiology, Lund University, Sweden. Use of ximelagatran was in some patients associated with an elevation of liver enzymes (ALAT >3XULN) which were typically transient, not associated with specific clinical symptoms, and decreased towards normal whether or not treatment was continued or stopped. Ximelagatran is currently under regulatory review in the EU and US for key chronic-use indications including the prevention of stroke and other thromboembolic complications associated with AF. It is now available in Germany, Sweden, Portugal and Finland in its first indication: the prevention of venous thromboembolic events (VTE) in patients undergoing elective hip or knee replacement surgery (orthopaedic surgery). A submission for prevention of VTE in major elective orthopaedic surgery (knee replacement) has also been filed in the US to the FDA. B Olsson (Lund, SE) ***** This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2004. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology European Society of Cardiology (ESC) |
|||||||||||||||||||||
| Related Stroke Current Events and Stroke News Articles New understanding about mechanism for cell death after stroke leads to possible therapy Scientists at the Brain Research Centre, a partnership of the University of British Columbia Faculty of Medicine and Vancouver Coastal Health Research Institute, have uncovered new information about the mechanism by which brain cells die following a stroke, as well as a possible way to mitigate that damage. Surgery not linked to memory problems in older patients For years, it has been widely assumed that older adults may experience memory loss and other cognitive problems following surgery. But a new study from researchers at Washington University School of Medicine in St. Louis questions those assumptions. Pushing the brain to find new pathways Until recently, scientists believed that, following a stroke, a patient had about six months to regain any lost function. After that, patients would be forced to compensate for the lost function by focusing on their remaining abilities. Night Beat, Overtime and a Disrupted Sleep Pattern Can Harm Officers' Health A police officer who works the night shift, typically from 8 p.m. to 4 a.m., already is at a disadvantage when it comes to getting a good "night's" sleep. Vitamin B niacin offers no extra benefit to statin therapy in seniors already diagnosed with CAD The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. The benefits of exercise Physical exercise is one of the most effective methods of preventing disease. The current issue of Deutsches Arzteblatt International is devoted to this important topic. Heart and bone damage from low vitamin D tied to declines in sex hormones Researchers at Johns Hopkins are reporting what is believed to be the first conclusive evidence in men that the long-term ill effects of vitamin D deficiency are amplified by lower levels of the key sex hormone estrogen, but not testosterone. New study links vitamin D deficiency to cardiovascular disease and death While mothers have known that feeding their kids milk builds strong bones, a new study by researchers at the Heart Institute at Intermountain Medical Center in Salt Lake City suggests that Vitamin D contributes to a strong and healthy heart as well - and that inadequate levels of the vitamin may significantly increase a person's risk of stroke, heart disease, and death, even among people who've never had heart disease. Early end to key study on benefits of niacin, a B vitamin, in keeping arteries open was premature Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Study finds many people with hemianopia have difficulty detecting pedestrians while driving, advocates for individual testing Schepens Eye Research Institute scientists have found that--when tested in a driving simulator--patients with hemianopia (blindness in one half of the visual field in both eyes) have significantly more difficulty detecting pedestrians (on their blind side) than normally sighted people. More Stroke Current Events and Stroke News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||